{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:28:45Z","timestamp":1791066525124,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T00:00:00Z","timestamp":1374796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust (UK)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Great Ormond Street Hospital Children's Charity (UK)"},{"DOI":"10.13039\/100011102","name":"European Union 7th Framework Programme","doi-asserted-by":"crossref","award":["PERSIST 222878"],"award-info":[{"award-number":["PERSIST 222878"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.gene.2013.03.098","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T10:49:43Z","timestamp":1365245383000},"page":"174-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Gene therapy for PIDs: Progress, pitfalls and prospects"],"prefix":"10.1016","volume":"525","author":[{"given":"Sayandip","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2013.03.098_bb0005","article-title":"Ten years of gene therapy for primary immune deficiencies","volume":"682\u2013689","author":"Aiuti","year":"2009","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.gene.2013.03.098_bb0010","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.gene.2013.03.098_bb0015","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1172\/JCI31666","article-title":"Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy","volume":"117","author":"Aiuti","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.gene.2013.03.098_bb0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0025","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.coi.2012.07.012","article-title":"Gene therapy for primary immunodeficiencies: part 2","volume":"24","author":"Aiuti","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0140-6736(03)12513-5","article-title":"Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968\u201399","volume":"361","author":"Antoine","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2013.03.098_bb0035","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/mp200132u","article-title":"Development of novel efficient SIN vectors with improved safety features for Wiskott\u2013Aldrich syndrome stem cell based gene therapy","volume":"8","author":"Avedillo","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.gene.2013.03.098_bb0040","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-05-221606","article-title":"Restoration of NET formation by gene therapy in CGD controls aspergillosis","volume":"114","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0045","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jaci.2011.01.021","article-title":"Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent","volume":"127","author":"Bianchi","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0050","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.gene.2013.03.098_bb0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/MOP.0b013e32834cd67a","article-title":"Gene therapy for primary immunodeficiency","volume":"23","author":"Booth","year":"2011","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.gene.2013.03.098_bb0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients","volume":"270","author":"Bordignon","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.gene.2013.03.098_bb0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1073\/pnas.97.1.274","article-title":"Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor","volume":"97","author":"Bousso","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2013.03.098_bb0070","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott\u2013Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0075","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0080","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2012-02-408591","article-title":"Gene therapy\/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction","volume":"120","author":"Carbonaro","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0085","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1182\/blood-2010-05-283523","article-title":"High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors","volume":"116","author":"Cattoglio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.coi.2012.08.008","article-title":"Gene therapy for primary immunodeficiencies: part 1","volume":"24","author":"Cavazzana-Calvo","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2006-11-058933","article-title":"Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency","volume":"110","author":"Chinen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0100","doi-asserted-by":"crossref","first-page":"e1000491","DOI":"10.1371\/journal.pgen.1000491","article-title":"Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy","volume":"5","author":"Dave","year":"2009","journal-title":"PLoS Genet."},{"key":"10.1016\/j.gene.2013.03.098_bb0105","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/mt.2011.178","article-title":"Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy","volume":"19","author":"Deichmann","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/hum.2006.17.303","article-title":"Efficacy of gene therapy for Wiskott\u2013Aldrich syndrome using a WAS promoter\/cDNA-containing lentiviral vector and nonlethal irradiation","volume":"17","author":"Dupre","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0115","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/S0140-6736(08)60874-0","article-title":"Gene therapy of inherited diseases","volume":"371","author":"Fischer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2013.03.098_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14712598.8.2.181","article-title":"Development of lentiviral gene therapy for Wiskott Aldrich syndrome","volume":"8","author":"Galy","year":"2008","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0125","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2013.03.098_bb0130","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood-2009-06-189209","article-title":"How I treat ADA deficiency","volume":"114","author":"Gaspar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001522","article-title":"Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy","volume":"2","author":"Gentner","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0150","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000072457","article-title":"Gene therapy for chronic granulomatous disease","volume":"110","author":"Goebel","year":"2003","journal-title":"Acta Haematol."},{"key":"10.1016\/j.gene.2013.03.098_bb0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2010.232","article-title":"Gene therapy of chronic granulomatous disease: the engraftment dilemma","volume":"19","author":"Grez","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0160","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.gene.2013.03.098_bb0170","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.gene.2013.03.098_bb0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0180","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.gene.2013.03.098_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2249.2008.03644.x","article-title":"Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry","volume":"152","author":"Jones","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0190","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0195","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0200","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/MOP.0b013e328359e480","article-title":"Gene therapy for primary immunodeficiencies","volume":"24","author":"Kildebeck","year":"2012","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.gene.2013.03.098_bb0205","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nbt1353","article-title":"Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery","volume":"25","author":"Lombardo","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.gene.2013.03.098_bb0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1634\/stemcells.18-2-155","article-title":"Use of serum-free medium with fibronectin fragment enhanced transduction in a system of gas permeable plastic containers to achieve high levels of retrovirus transduction at clinical scale","volume":"18","author":"Malech","year":"2000","journal-title":"Stem Cells"},{"key":"10.1016\/j.gene.2013.03.098_bb0215","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1073\/pnas.94.22.12133","article-title":"Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease","volume":"94","author":"Malech","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2013.03.098_bb0220","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2002-02-0578","article-title":"Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene","volume":"101","author":"Marodon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/156652312799789253","article-title":"Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency","volume":"12","author":"Montiel-Equihua","year":"2012","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0230","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott\u2013Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980\u20132009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2004.04.005","article-title":"Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells","volume":"10","author":"Moreau","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0240","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1182\/blood-2008-09-177923","article-title":"Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency","volume":"113","author":"Neven","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0b013e32834cb943","article-title":"Primary immunodeficiency modeling with induced pluripotent stem cells","volume":"11","author":"Pessach","year":"2011","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0255","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaci.2010.11.008","article-title":"Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies","volume":"127","author":"Pessach","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0260","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/gt.2009.127","article-title":"Progress and prospects: gene therapy for inherited immunodeficiencies","volume":"16","author":"Qasim","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0265","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1089\/hum.2012.116","article-title":"Gene therapy for primary immunodeficiencies","volume":"23","author":"Rivat","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc3179","article-title":"Safe harbours for the integration of new DNA in the human genome","volume":"12","author":"Sadelain","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2013.03.098_bb0275","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/mt.2012.23","article-title":"Preclinical Safety and Efficacy of Human CD34(+) Cells Transduced With Lentiviral Vector for the Treatment of Wiskott\u2013Aldrich Syndrome","volume":"21","author":"Scaramuzza","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0285","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/mt.2009.59","article-title":"A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity","volume":"17","author":"Scobie","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2013.03.098_bb0290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.23.021704.115653","article-title":"How neutrophils kill microbes","volume":"23","author":"Segal","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0295","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.bbmt.2010.09.008","article-title":"Chronic granulomatous disease: lessons from a rare disorder","volume":"17","author":"Segal","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.gene.2013.03.098_bb0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06880.x","article-title":"Modern management of chronic granulomatous disease","volume":"140","author":"Seger","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.gene.2013.03.098_bb0305","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nbt.2290","article-title":"Gene therapy matures in the clinic","volume":"30","author":"Seymour","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.gene.2013.03.098_bb0310","doi-asserted-by":"crossref","first-page":"11730","DOI":"10.1073\/pnas.0603635103","article-title":"Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy","volume":"103","author":"Shou","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2013.03.098_bb0315","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2013.03.098_bb0320","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nri2724","article-title":"WASP: a key immunological multitasker","volume":"10","author":"Thrasher","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.gene.2013.03.098_bb0325","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2004-12-4837","article-title":"Failure of SCID-X1 gene therapy in older patients","volume":"105","author":"Thrasher","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0330","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature03556","article-title":"Highly efficient endogenous human gene correction using designed zinc-finger nucleases","volume":"435","author":"Urnov","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.gene.2013.03.098_bb0335","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","article-title":"Chronic granulomatous disease. Report on a national registry of 368 patients","volume":"79","author":"Winkelstein","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gene.2013.03.098_bb0340","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1126\/science.1207773","article-title":"Targeted genome editing across species using ZFNs and TALENs","volume":"333","author":"Wood","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.gene.2013.03.098_bb0345","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1182\/blood-2006-12-060814","article-title":"Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells","volume":"110","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.gene.2013.03.098_bb0350","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1182\/blood-2010-12-328161","article-title":"Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting","volume":"117","author":"Zou","year":"2011","journal-title":"Blood"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111913003673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111913003673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:23:01Z","timestamp":1588828981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111913003673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0378111913003673"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2013.03.098","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for PIDs: Progress, pitfalls and prospects","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2013.03.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}